Loading clinical trials...
Loading clinical trials...
About 65% of patients with severe Alzheimer's Disease (AD) will have symptoms of agitation. There are drawbacks associated with the currently available therapeutic interventions for agitation associat...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Forest Laboratories
NCT07033494 · Early Alzheimer's Disease
NCT06159673 · Alzheimer's Disease Psychosis
NCT07457138 · Subjective Cognitive Decline (SCD), Functional Cognitive Disorder, and more
NCT07422857 · Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia
NCT07214727 · Alzheimer's Disease
The Forves Norris MDA/ALS Research Center
San Francisco, California
Coastal Communities Hospital
Westminster, California
Alzheimer's Disease Research Unit
New Haven, Connecticut
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions